Anti-p53 [Pab DO-2]

Cat. #151292

Anti-p53 [Pab DO-2]

Cat. #: 151292

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: p53 (N terminus)

Class: Monoclonal

Application: IHC ; IP ; WB

Reactivity: Human

Host: Mouse


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: David Lane

Institute: University of Dundee

Primary Citation: Vojtesek et al. 1992. J Immunol Methods. 151(1-2):237-44. PMID: 1378473.

Tool Details
Target Details
Related Tools

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-p53 [Pab DO-2]
  • Research fields: Apoptosis and autophagy;Cancer;Cell biology;Genetics
  • Clone: Pab DO-2
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 53 kDa
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; IP ; WB
  • Description: A monoclonal p53 antibody, the epitope recognised is in the N terminus of p53.
  • Immunogen: p53
  • Isotype: IgG1
  • Recommended controls: MDA-MB-231 cell line

Target Details

  • Target: p53 (N terminus)
  • Molecular weight: 53 kDa
  • Tissue cell line specificity: MDA-MB-231 cell line
  • Target background: p53 is a crucial tumour suppressor involved in over 50% of cancers. It acts as a stress-responsive transcription factor and plays a vital role in regulating cell cycle arrest, promoting apoptosis, maintaining genomic stability, controlling the cell cycle, and inhibiting angiogenesis. Known as the "guardian of the genome," p53 prevents gene mutations. Mutations in the p53 gene are common in human cancers, resulting in dysfunctional proteins unable to bind to DNA. This loss of function compromises p53's tumour suppressor activity. While p53 is typically found in low levels in healthy cells due to its short lifespan, disease states lead to increased expression driven by somatic mutations. This heightened expression is believed to contribute to cellular transformation and malignancy. DO-2 recognises an epitope specific for the N terminus region of p53, between aa 10-16.


  • Application: IHC ; IP ; WB


  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: '-15° C to -25° C
  • Shipping conditions: Shipping at 4° C

Related Tools

  • Related tools: Anti-p53 [Pab DO-1]


  • Sonnemann et al. 2011. Eur J Cancer. 47(9):1432-41. PMID: 21334198.
  • Zaman et al. 2007. Cancer Res. 67(20):10078-86. PMID: 17942942.
  • Stephen et al. 1995. J Mol Biol. 248(1):58-78. PMID: 7537340.
  • Vojtesek et al. 1992. J Immunol Methods. 151(1-2):237-44. PMID: 1378473.